Long-term outcomes after appendicectomy as experimental treatment for patients with therapy-refractory ulcerative colitis

Maud A. Reijntjes; Lianne Heuthorst; Merle E. Stellingwerf; Geert R. D'Haens; Wilhelmus A. Bemelman; Christianne J. Buskens

doi:https://doi.org/10.1093/bjs/znad425

Long-term outcomes after appendicectomy as experimental treatment for patients with therapy-refractory ulcerative colitis

Maud A. Reijntjes, Lianne Heuthorst, Merle E. Stellingwerf, Geert R. D'Haens, Wilhelmus A. Bemelman, Christianne J. Buskens

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Article number	znad425
Journal	The British journal of surgery
Volume	111
Issue number	1
DOIs	https://doi.org/10.1093/bjs/znad425
Publication status	Published - 1 Jan 2024

Access to Document

https://doi.org/10.1093/bjs/znad425

Cite this

@article{e75923271b9b48549fed943d8d4a0e89,

title = "Long-term outcomes after appendicectomy as experimental treatment for patients with therapy-refractory ulcerative colitis",

author = "Reijntjes, {Maud A.} and Lianne Heuthorst and Stellingwerf, {Merle E.} and D'Haens, {Geert R.} and Bemelman, {Wilhelmus A.} and Buskens, {Christianne J.}",

note = "Funding Information: G.R.D{\textquoteright}H. has served as advisor for Abbvie, Ablynx, Active Biotech AB, Agomab Therapeutics, Alimentiv, Allergan, Alphabiomics, Amakem, Amgen, AM Pharma, Applied Molecular Therapeutics, Arena Pharmaceuticals, AstraZeneca, Avaxia, Biogen, Bristol Meyers Squibb/Celgene, Boehringer Ingelheim, Celltrion, Cosmo, DSM Pharma, Echo Pharmaceuticals, Eli Lilly, Engene, Exeliom Biosciences, Ferring, DrFALK Pharma, Galapagos, Genentech/Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Kintai Therapeutics, Lument, Lycera, Medimetrics, Takeda, Medtronic, Mitsubishi Pharma, Merck Sharp & Dohme, Mundipharma, Nextbiotics, Novonordisk, Otsuka, Photopill, ProciseDx, Prodigest, Prometheus Laboratories/Nestle, Progenity, Protagonist, RedHill, Salix, Samsung Bioepis, Sandoz, Seres/Nestec/Nestle, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant, and Vifor; and received speaker{\textquoteright}s fees from Abbvie, Biogen, Ferring, Galapagos/Gilead, Johnson and Johnson, Merck Sharp Dohme, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Millenium/Takeda, Tillotts, and Vifor. W.A.B. has received research funding from Vifor; served as a consultant for Takeda and Braun; and received speaker{\textquoteright}s fees from Takeda, Johnson, Braun, and Medtronic. C.J.B. has an unrestricted grant from Boehringer Ingelheim and Roche; and reports consultancy fees or speaker{\textquoteright}s honoraria from AbbVie, Merck Sharp & Dohme, Tillotts, Janssen, and Takeda. The authors declare no other conflict of interest.",

year = "2024",

month = jan,

day = "1",

doi = "https://doi.org/10.1093/bjs/znad425",

language = "English",

volume = "111",

journal = "The British journal of surgery",

issn = "0007-1323",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

TY - JOUR

T1 - Long-term outcomes after appendicectomy as experimental treatment for patients with therapy-refractory ulcerative colitis

AU - Reijntjes, Maud A.

AU - Heuthorst, Lianne

AU - Stellingwerf, Merle E.

AU - D'Haens, Geert R.

AU - Bemelman, Wilhelmus A.

AU - Buskens, Christianne J.

N1 - Funding Information: G.R.D’H. has served as advisor for Abbvie, Ablynx, Active Biotech AB, Agomab Therapeutics, Alimentiv, Allergan, Alphabiomics, Amakem, Amgen, AM Pharma, Applied Molecular Therapeutics, Arena Pharmaceuticals, AstraZeneca, Avaxia, Biogen, Bristol Meyers Squibb/Celgene, Boehringer Ingelheim, Celltrion, Cosmo, DSM Pharma, Echo Pharmaceuticals, Eli Lilly, Engene, Exeliom Biosciences, Ferring, DrFALK Pharma, Galapagos, Genentech/Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Kintai Therapeutics, Lument, Lycera, Medimetrics, Takeda, Medtronic, Mitsubishi Pharma, Merck Sharp & Dohme, Mundipharma, Nextbiotics, Novonordisk, Otsuka, Photopill, ProciseDx, Prodigest, Prometheus Laboratories/Nestle, Progenity, Protagonist, RedHill, Salix, Samsung Bioepis, Sandoz, Seres/Nestec/Nestle, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant, and Vifor; and received speaker’s fees from Abbvie, Biogen, Ferring, Galapagos/Gilead, Johnson and Johnson, Merck Sharp Dohme, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Millenium/Takeda, Tillotts, and Vifor. W.A.B. has received research funding from Vifor; served as a consultant for Takeda and Braun; and received speaker’s fees from Takeda, Johnson, Braun, and Medtronic. C.J.B. has an unrestricted grant from Boehringer Ingelheim and Roche; and reports consultancy fees or speaker’s honoraria from AbbVie, Merck Sharp & Dohme, Tillotts, Janssen, and Takeda. The authors declare no other conflict of interest.

PY - 2024/1/1

Y1 - 2024/1/1

UR - http://www.scopus.com/inward/record.url?scp=85181847915&partnerID=8YFLogxK

U2 - https://doi.org/10.1093/bjs/znad425

DO - https://doi.org/10.1093/bjs/znad425

M3 - Article

C2 - 38181182

SN - 0007-1323

VL - 111

JO - The British journal of surgery

JF - The British journal of surgery

IS - 1

M1 - znad425

ER -

Long-term outcomes after appendicectomy as experimental treatment for patients with therapy-refractory ulcerative colitis

Access to Document

Other files and links

Cite this